ADMA Biologics (NASDAQ:ADMA) Earns “Neutral” Rating from Cantor Fitzgerald

ADMA Biologics (NASDAQ:ADMA)‘s stock had its “neutral” rating reissued by stock analysts at Cantor Fitzgerald in a report released on Thursday, MarketBeat.com reports.

Other research analysts also recently issued reports about the stock. Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. Zacks Research upgraded shares of ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 2nd. Finally, Wall Street Zen raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. Two equities research analysts have rated the stock with a Strong Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, ADMA Biologics currently has a consensus rating of “Buy” and an average price target of $32.00.

ADMA Biologics Price Performance

Shares of NASDAQ ADMA opened at $9.25 on Thursday. The firm has a market capitalization of $2.20 billion, a PE ratio of 15.42 and a beta of 0.51. The company has a debt-to-equity ratio of 0.16, a quick ratio of 3.74 and a current ratio of 6.71. ADMA Biologics has a fifty-two week low of $7.21 and a fifty-two week high of $25.67. The stock’s 50-day simple moving average is $15.60 and its 200-day simple moving average is $16.42.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.20. ADMA Biologics had a net margin of 28.80% and a return on equity of 37.52%. The business had revenue of $139.16 million during the quarter, compared to analysts’ expectations of $139.80 million. During the same quarter in the prior year, the business posted $0.46 EPS. The company’s revenue for the quarter was up 18.4% on a year-over-year basis. As a group, equities research analysts forecast that ADMA Biologics will post 0.51 EPS for the current fiscal year.

Insider Buying and Selling

In related news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of ADMA Biologics stock in a transaction on Monday, March 9th. The shares were sold at an average price of $15.63, for a total value of $157,800.48. Following the completion of the sale, the chief operating officer owned 466,600 shares in the company, valued at approximately $7,292,958. The trade was a 2.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Steve Elms acquired 7,000 shares of the firm’s stock in a transaction on Thursday, March 5th. The shares were bought at an average cost of $15.67 per share, with a total value of $109,690.00. Following the completion of the acquisition, the director owned 2,038,730 shares in the company, valued at $31,946,899.10. This represents a 0.34% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 3.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On ADMA Biologics

Hedge funds have recently added to or reduced their stakes in the business. Summit Securities Group LLC bought a new stake in shares of ADMA Biologics in the 4th quarter worth approximately $29,000. Salomon & Ludwin LLC acquired a new position in shares of ADMA Biologics during the third quarter worth approximately $25,000. Rothschild Investment LLC boosted its position in shares of ADMA Biologics by 373.8% during the third quarter. Rothschild Investment LLC now owns 1,895 shares of the biotechnology company’s stock worth $28,000 after buying an additional 1,495 shares during the period. Optima Capital LLC acquired a new position in shares of ADMA Biologics during the fourth quarter worth approximately $36,000. Finally, Clearstead Advisors LLC grew its holdings in ADMA Biologics by 55.7% in the 3rd quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock worth $33,000 after buying an additional 795 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

Key ADMA Biologics News

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: Company issues formal refutation of Culper Research’s allegations, calling the report “unsubstantiated, misleading and inaccurate” and defending ASCENIV’s competitive position and revenue recognition. ADMA refutes short-seller claims
• Positive Sentiment: Market coverage notes a rebound after the company’s rebuttal — headlines and articles report ADMA “gains” as traders react to management’s statements. ADMA gains after refuting claims
• Positive Sentiment: Analysts and media flag market attention including Nasdaq reactions and commentary that the company is actively addressing investor concerns — helpful for short‑term sentiment. Market attention coverage
• Neutral Sentiment: Unusual options activity was reported (large call buying), suggesting speculative positioning that can amplify intraday moves but not fundamental direction. (Options volume reported in market notices.)
• Neutral Sentiment: Context pieces note ADMA is down significantly since its last earnings release, highlighting volatility tied to recent results and expectations — useful for evaluating risk vs. reward. Zacks: stock down since earnings
• Negative Sentiment: Multiple securities‑fraud investigations and investor alerts have been launched by a number of law firms after the short report and the subsequent price decline — this increases legal risk and could pressure the stock. Investor investigations announced
• Negative Sentiment: Short‑seller allegations (including claims of channel stuffing) remain in circulation via reports and investor alerts; third‑party scrutiny prompted steep intraday declines last week and remains a key downside risk. Investor alert on short‑seller report
• Negative Sentiment: Cantor Fitzgerald moved the stock after the short‑report fallout (coverage/ratings action reported), adding analyst pressure on sentiment. Cantor Fitzgerald downgrade

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.